Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells

被引:32
作者
Wu, Yi-Xin [1 ]
Fang, Xin [2 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Biochem, Higasi ku, Hamamatsu, Shizuoka 4313192, Japan
[2] Hamamatsu Univ Sch Med, Mol Imaging Frontier Res Ctr, Hamamatsu, Shizuoka 4313192, Japan
关键词
flavonoids; proteasomes; inhibitors; DIETARY FLAVONOIDS; PATHWAY; ANTICANCER;
D O I
10.1055/s-0029-1186004
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
The ubiquitin-proteasome pathway has an important role in regulating apoptosis and the cell cycle. The function of proteasomes is mediated by three main catalytic activities: (1) chymotrypsin-like (CT-L), (2) trypsin-like (T-L), and (3) peptidylglutamyl peptide hydrolyzing (PGPH). Recently, proteasome inhibitors have been revealed to have an antitumor effect, and have been used to treat cancers such as multiple myeloma. Previous studies have reported that some flavonoids can inhibit proteasome activity in tumor cells. To further investigate the proteasome-inhibitory mechanism of flavonoids, we examined the effects of the plant flavonoids apigenin, chrysin, and luteolin on the three individual catalytic activities in various cancer cell lines. Using fluorogenic substrates specific for proteasome catalytic subunits, we demonstrated the subunit specificity of each flavonoid. Addition of apigenin, chrysin and luteolin inhibited CT-L and T-L catalytic activities in a dose-dependent manner, whereas their effect on PGPH catalytic activity was weak. Our study suggested that these flavonoids have a specific role in inhibition of CT-L and T-L proteasome catalytic activities.
引用
收藏
页码:128 / 132
页数:5
相关论文
共 19 条
[1]   Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells [J].
Chen, D ;
Daniel, KG ;
Chen, MS ;
Kuhn, DJ ;
Landis-Piwowar, KR ;
Dou, QP .
BIOCHEMICAL PHARMACOLOGY, 2005, 69 (10) :1421-1432
[2]   Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells [J].
Chen, Di ;
Chen, Marina S. ;
Cui, Qiuzhi Cindy ;
Yang, Huanjie ;
Dou, Q. Ping .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :1935-1945
[3]  
Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO
[4]  
2-Q
[5]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160
[6]   Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132 [J].
Crawford, Lisa J. A. ;
Walker, Brian ;
Ovaa, Huib ;
Chauhan, Dharminder ;
Anderson, Kenneth C. ;
Morris, Treen C. M. ;
Irvine, Alexandra E. .
CANCER RESEARCH, 2006, 66 (12) :6379-6386
[7]   Comparative Anticancer and Antioxidant Activities of Different Ingredients of Ginkgo biloba Extract (EGb 761) [J].
Feng, Xiaolong ;
Zhang, Lantong ;
Zhu, Huiming .
PLANTA MEDICA, 2009, 75 (08) :792-796
[8]   The catalytic sites of 20S proteasomes and their role in subunit maturation:: A mutational and crystallographic study [J].
Groll, M ;
Heinemeyer, W ;
Jäger, S ;
Ullrich, T ;
Bochtler, M ;
Wolf, DH ;
Huber, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) :10976-10983
[9]   Velcade®:: USFDA approval for the treatment of multiple myeloma progressing on prior therapy [J].
Kane, RC ;
Bross, PF ;
Farrell, AT ;
Pazdur, R .
ONCOLOGIST, 2003, 8 (06) :508-513
[10]   Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein [J].
Kazi, A ;
Daniel, KG ;
Smith, DM ;
Kumar, NB ;
Dou, QP .
BIOCHEMICAL PHARMACOLOGY, 2003, 66 (06) :965-976